E
Estelle Lach-Trifilieff
Researcher at Novartis
Publications - 17
Citations - 1933
Estelle Lach-Trifilieff is an academic researcher from Novartis. The author has contributed to research in topics: Skeletal muscle & Myostatin. The author has an hindex of 14, co-authored 17 publications receiving 1558 citations. Previous affiliations of Estelle Lach-Trifilieff include Harvard University.
Papers
More filters
Journal ArticleDOI
GDF11 Increases with Age and Inhibits Skeletal Muscle Regeneration.
Marc A. Egerman,Samuel M. Cadena,Jason A. Gilbert,Angelika Meyer,Hallie N. Nelson,Susanne E. Swalley,Carolyn Mallozzi,Carsten Jacobi,Lori L. Jennings,Ieuan Clay,Gaëlle Laurent,Shenglin Ma,Sophie Brachat,Estelle Lach-Trifilieff,Tea Shavlakadze,Anne-Ulrike Trendelenburg,Andrew S. Brack,David J. Glass +17 more
TL;DR: A GDF11-specific immunoassay is developed and a trend toward increased GDF 11 levels in sera of aged rats and humans is shown and GDF12 could be a target for pharmacologic blockade to treat age-related sarcopenia.
Journal ArticleDOI
An Antibody Blocking Activin Type II Receptors Induces Strong Skeletal Muscle Hypertrophy and Protects from Atrophy
Estelle Lach-Trifilieff,Giulia Minetti,Kelly-Ann Sheppard,Chikwendu Ibebunjo,Jerome N. Feige,Steffen Hartmann,Sophie Brachat,Helene Rivet,Claudia Koelbing,Frederic Morvan,Shinji Hatakeyama,David J. Glass +11 more
TL;DR: A novel, human anti-ActRII antibody is developed to prevent binding of ligands to the receptors and thus inhibit downstream signaling in the myostatin/activin type II receptor pathway, highlighting the compelling therapeutic potential of BYM338 for the treatment of skeletal muscle atrophy and weakness in multiple settings.
Journal ArticleDOI
The TWEAK–Fn14 system is a critical regulator of denervation-induced skeletal muscle atrophy in mice
Ashwani Mittal,Shephali Bhatnagar,Akhilesh Kumar,Estelle Lach-Trifilieff,Sandrine Wauters,Hong Li,Denys Y. Makonchuk,David J. Glass,Ashok Kumar +8 more
TL;DR: The TNF-related cytokine TWEAK promotes skeletal muscle atrophy that is associated with classical disuse syndromes.
Journal ArticleDOI
Treatment of sporadic inclusion body myositis with bimagrumab
Anthony A. Amato,Kumaraswamy Sivakumar,Namita Goyal,William S. David,Mohammad Salajegheh,Jens Praestgaard,Estelle Lach-Trifilieff,Anne-Ulrike Trendelenburg,Didier Laurent,David J. Glass,Ronenn Roubenoff,Brian Tseng,Steven A. Greenberg +12 more
TL;DR: This study provides Class I evidence that for patients with inclusion body myositis, bimagrumab increases thigh muscle volume at 8 weeks, and inhibition of ActRII increased muscle mass and function in this pilot trial, offering a potential novel treatment of sIBM.
Journal ArticleDOI
Treatment of Sarcopenia with Bimagrumab: Results from a Phase II, Randomized, Controlled, Proof-of-Concept Study
Daniel Rooks,Jens Praestgaard,Sam Hariry,Didier Laurent,Olivier Petricoul,Robert G. Perry,Estelle Lach-Trifilieff,Ronenn Roubenoff +7 more
TL;DR: To assess the effects of bimagrumab on skeletal muscle mass and function in older adults with sarcopenia and mobility limitations, a large number of patients with these conditions are referred to a single hospital for evaluation.